InvestorsHub Logo
Followers 971
Posts 383038
Boards Moderated 6
Alias Born 06/24/2011

Re: None

Monday, 10/23/2023 11:41:36 AM

Monday, October 23, 2023 11:41:36 AM

Post# of 118408
"A second unrelated CRO is currently performing qRT-PCR tests to determine if NR2F6 mRNA is elevated or inhibited by our CAR in T-Cells," says Dr. Harry Lander, Chief Scientific Consultant to the Company." If NR2F6 mRNA is suppressed (stimulating certain immune functions) then this product shows potential for treatment of cancer and if NR2F6 mRNA is elevated (suppressing certain immune functions) then the product shows potential for treatment of autoimmune disorders."
Bullish
Bullish